Clinical proof of principle for ChimeriVax™: Recombinant live, attenuated vaccines against flavivirus infections

Vaccine

Volumn 20, Issue 7-8, 2002, Pages 1004-1018

  Monath, Thomas P ^a   McCarthy, Karen ^a   Bedford, Philip ^a   Johnson, Casey T ^b   Nichols, Richard ^a   Yoksan, Sutee ^c   Marchesani, Ron ^a   Knauber, Michael ^a   Wells, Keith H ^a   Arroyo, Juan ^a   Guirakhoo, Farshad ^a  

^a Acambis   (United States)

^b Pharmaceutical Research Associates Inc   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

ChimeriVax ; Flavivirus infections; Vaccine

Indexed keywords

CHIMERIVAX; JAPANESE ENCEPHALITIS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; YELLOW FEVER VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EPIDEMIC ENCEPHALITIS; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNOGENICITY; INJECTION SITE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION; VIREMIA;

ADULT; ALANINE TRANSAMINASE; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; FLAVIVIRUS INFECTIONS; HUMANS; IMMUNOGLOBULIN M; JAPANESE ENCEPHALITIS VACCINES; LEUKOCYTE COUNT; MALE; RECOMBINANT FUSION PROTEINS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIREMIA; YELLOW FEVER VACCINE;

EID: 18544410924     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00457-1     Document Type: Article

References (39)

1. The Flaviviruses
2. Yellow fever
3. Yellow fever/Japanese encephalitis chimaeric viruses: Construction and biological properties
4. Vaccine development against dengue and Japanese encephalitis: Report of a World Health Organization meeting
5. Immunogenicity, genetic stability and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax™-JE) as a live, attenuated vaccine candidate against Japanese encephalitis
6. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: Dose-response effectiveness and extended safety testing in Rhesus monkeys
7. Immunogenicity of live, attenuated SA14-14-2 Japanese encephalitis vaccine - A comparison of 1- and 3-month immunization schedules
8. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in non-human primates
9. Construction, safety, and immunogenicity in non-human primates of a chimeric yellow fever-dengue virus tetravalent vaccine
10. West Nile vaccine
11. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes
12. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and non-structural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates
13. Yellow fever vaccine: Direct challenge of monkeys given graded doses of 17D vaccine
14. A plaque reduction test for dengue virus neutralizing antibodies
15. Genetic variation of Japanese encephalitis virus in nature
16. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses
17. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate
18. Selection of a better immunogenic and highly attenuated live vaccine virus strain of JE. I. Some biological characteristics of SA14-14-2 mutant
19. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): A case-control study
20. Molecular basis for attenuation of neurovirulence of a yellow fever/Japanese encephalitis (ChimeriVax-JE) viral vaccine
21. Yellow fever vaccines
22. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: A case-control study
23. Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus
24. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection
25. Immunological studies with group B arthropod-borne viruses. III. Response of human subjects to revaccination with 17D strain yellow fever vaccine
26. Effect of immunity to the carrier protein on antibody responses to Haempophilus influenzae type b conjugate vaccines
27. Original antigenic sin in dengue
28. Clinical and serological response of man to immunization with attenuated dengue and yellow fever viruses
29. Immunologocal studies with Group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus
30. Serological response to Japanese B encephalitis vaccine of children and horses immune to St. Louis virus
31. Hemagglutination with arthropod-borne viruses
32. Protection against yellow fever in monkeys by immunization with yellow fever virus non-structural protein NS1
33. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines
34. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus
35. Behavior of 17D yellow fever virus in rhesus monkeys. Relation to substrain
36. In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination
37. Immunology
38. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX™ and YF-VAX®) in a Phase III multicenter, double-blind clinical trial